Dr Nicole Saphier, a radiologist at Memorial Sloan Kettering Cancer Center in New Jersey and former Fox News contributor, is set to appear before a Senate confirmation hearing on Wednesday as President Trump’s nominee for surgeon general. The financial disclosure she filed last week reveals that she earned $270,605 from Empower MD, the company that markets her supplement line Drop RX, and lists the firm’s valuation between $100,001 and $250,000. She has undertaken to divest from her holdings in tobacco corporations within 90 days of any confirmation, though the filings also show sizable stakes in Philip Morris International and British American Tobacco Industries, jointly held with her husband. In addition to the supplement venture, Saphier reported investments in pharmaceutical and healthcare technology firms, as well as in fossil‑fuel and food companies such as Coca‑Cola, PepsiCo and McDonald’s.
Public Health Concerns Over Supplements
Critics have raised alarms about the nature of the supplement business, noting that many products lack robust scientific validation. Dr Peter Lurie of the Center for Science in the Public Interest argued that investing in or running a supplement company is incompatible with the credibility required of a public health chief, describing the industry as a haven for “grifters” who sell unproven remedies. The FDA has previously warned that kava kava, an ingredient found in one of the Drop RX formulations, can cause liver damage and is prohibited for US military personnel. Although most Drop RX products are currently unavailable, a “Soothe” blend containing turmeric and ginger continues to be sold on Amazon for $24.99.
Tobacco Holdings and Ethical Questions
The surgeon general’s office has long warned of the lethal consequences of tobacco use, yet Saphier’s disclosed interests tie her financially to a multinational tobacco company that markets cigarettes and reduced‑risk products worldwide. In an ethics agreement, she pledged to relinquish those stakes shortly after taking office, but the timing of the commitment has drawn sharp criticism. Lurie warned that it is “unimaginable” for a surgeon general to have personal financial ties to a product the office itself has declared deadly, suggesting that such a conflict should automatically disqualify a candidate.
Confirmation Process and Political Context
Saphier represents Trump’s third attempt to secure the surgeon general position; his previous two nominees failed to advance past the Senate. A White House spokesperson declined to comment, while spokesman Kush Desai characterised her as an accomplished physician who has been an outspoken critic of Covid‑19 mandates, the politicisation of science and the chronic disease epidemic. He asserted that she would serve as a “powerful asset” for the administration and work tirelessly to realise the goals of the “Make America Healthy Again” agenda.
Why it Matters
The intersection of Saphier’s commercial activities and her prospective public‑health role raises profound questions about regulatory capture and the integrity of America’s health guidance. If confirmed, she would oversee a portfolio that includes both controversial supplements and substantial investments in tobacco, sectors that many health experts deem antithetical to public wellbeing. This conflict could undermine confidence in the surgeon general’s ability to prioritize evidence‑based policy, influence the nation’s chronic disease strategy, and affect the credibility of the “Maha” health initiative, with far‑reaching consequences for American health outcomes and the public’s trust in governmental health institutions.
